Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung CancerTony Mok, Vassiliki A. Papadimitrakopoulou, Alison Templeton et al.|New England Journal of Medicine|2016Cited by 3.3k
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancerGeoffrey R. Oxnard, Myung‐Ju Ahn, J.C.-H. Yang et al.|Annals of Oncology|2020Cited by 443
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III studyRobert L. Ferris, Lisa Licitra, Robert I. Haddad et al.|Annals of Oncology|2020Cited by 365
Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapySusan M. Domchek, Bella Kaufman, Carol Aghajanian et al.|Gynecologic Oncology|2015Cited by 300
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLCGilberto de Castro, Tony Mok, Naiyer A. Rizvi et al.|Journal of Thoracic Oncology|2022Cited by 72